In Brief: Metra Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Metra Biosystems: Gains 510(k) clearance for the use of the Pyrilinks-D bone resorption immunoassay to monitor anti-resorptive therapies, including Merck's Fosamax (alendronate), in the treatment and prevention of osteoporosis. The clearance is based upon a randomized, placebo-controlled clinical trial conducted by Merck to demonstrate the efficacy of alendronate in postmenopausal women diagnosed with osteoporosis. First cleared by the FDA in December 1995 for measuring bone resorption, Pyrilinks-D was used in the Merck trial to compare Dpd levels in subjects who received either alendronate and a calcium supplement or a calcium supplement alone...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.